Gilead Sciences, Inc. (GILD): This Biotech Leader Is Poised to Outperform

Page 1 of 2

Investing in biotech companies can be risky; developing new drugs is a long, expensive, and uncertain process, and there is always considerable regulatory risk in the industry. When it comes to Gilead Sciences, Inc. (NASDAQ:GILD), however, its dominant position in HIV treatment and the company’s growth prospects make it look like a long term winner.

Leadership

Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) is the undisputed leader in HIV treatments; the company makes more than 75% of its revenue from different drugs to fight the disease. Viread, Emtriva, and combo drug Truvada have been the key growth drivers for Gilead over the last years, but the all-in-one triple combination pill, Atripla, has been the most recent winner, and it now generates more than 30% of the company´s revenues.

Atripla combines Gilead Sciences, Inc. (NASDAQ:GILD)´s Truvada with Bristol Myers Squibb Co. (NYSE:BMY)’s Sustiva, and it’s the first pill approved by the FDA as a one single pill for HIV treatment. By providing a much simpler treatment, Atripla has material positive effects on patient compliance, which is a key factor when it comes to effectiveness in treatments. Besides, it makes the treatment more affordable.

Truvada, which has traditionally been used for HIV treatment, recently received approval from the FDA to be used as the first HIV prevention drug. This has raised some controversy among experts, but it has the potential to be a real game changer. The drug is approved for uninfected people who are at high risk of contracting HIV thorough sex, these include sex workers and people with partners who are HIV-positive or engage in high-risk behaviors, such as using IV drugs.

In the middle term, Stribilid is showing promising potential. This all-Gilead regimen containing a new integrase inhibitor entered the market in 2012, and it could lead Gilead Sciences, Inc. (NASDAQ:GILD) into the next phase of growth in HIV treatment. Stribilid will be facing strong competition from Merck & Co., Inc. (NYSE:MRK)´s well established drug Isentress which generated sales of 1.5 billion for the company in 2012, an increase of 11% versus 2011.

Although Merck has the leadership position in this segment, Gilead´s competitive strength in HIV treatment should not be underestimated, especially considering that Stribilid is off to an auspicating start.

Growth prospects

Speaking at the UBS Global Healthcare Conference in May of this year, Gilead´s management said that the company currently has the biggest amount of products in Phase 3 studies in its history. Not only when it comes to HIV treatment, but also for cardiovascular, respiratory, and oncology diseases, Gilead Sciences, Inc. (NASDAQ:GILD) has a promising pipeline.

Source Gilead investor fact sheet

One particularly exciting opportunity for the company is hepatitis-C treatment, and Gilead´s sofosbuvir drug has some very real chances at becoming a blockbuster in a gigantic market.

According to the company, the global prevalence of hepatitis-C virus is estimated to be 160 million people across all continents. Focusing specifically on the major markets: EU, U.S., Canada, Australia, Japan and Brazil, Gilead Sciences, Inc. (NASDAQ:GILD) estimates that there’s a prevalence about 12.6 million patients around the world, of which only about 36% are currently diagnosed and 4% currently in treatment.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!